TriSalus Life Sciences Receivables

The latest receivables for TLSI is $5.2M as of March 2026. That compares with $5.5M in the prior-year period — down 4.4% year over year. Investors often review this figure alongside TriSalus Life Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, TLSI's receivables moved from $5.5M to $5.2M — a 4.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TriSalus Life Sciences's operating scale or balance-sheet position.

A receivables figure of $5.2M for TLSI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting TLSI's receivables ($5.2M), review year-over-year change from $5.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.